Principles & People:
Ventria Bioscience believes in the inherent worth of all people, worldwide, and in the power of science to improve longevity and quality of life for everyone. Specifically, we believe the power of scientific innovation, combined with a values-guided entrepreneurial spirit, can solve some of the most vexing challenges facing humanity today.
- Ventria Bioscience values patient safety and health outcomes above all else.
- The people of Ventria Bioscience conduct our operations and our interactions with each other guided by the principles of honesty, integrity, respect, teamwork, transparency, and accountability toward each other and the company.
- We work with a sense of urgency, commitment, and entrepreneurship.
- We work to exceed customer and patient expectations for our products and services.
Every day, Ventria Bioscience’s employees focus their passion, skill, scientific and business expertise, entrepreneurial drive, and thirst for knowledge on solving some of the most challenging problems in global health. Our people and our company are driven by the scientific method and by our vision of improving longevity and quality of life for people all over the globe.
ExpressTec is a high-yield system for plant-based, eukaryotic expression and purification of recombinant proteins that are free from human, animal, or microbial contaminants. ExpressTec is able to produce commercial-scale yields of recombinant protein products from an organism that is widely recognized as safe.
ExpressTec produces as much as ten-fold more expression product of other plant expression systems, with recombinant protein yields that can be scaled from kilograms to hundreds of metric tons—all with a reduced carbon footprint compared to other recombinant biomanufacturing systems.
ExpressTec’s naturally high product yields and simple, aqueous purification process dramatically lower the cost of cGMP production to enable biomanufacturing of cost-effective therapeutics and bioreagents.
ExpressTec products are free of human, animal, and microbial contaminants, and our cGMP manufacturing process complies with all State, Federal and International regulatory standards for the production, processing, development, and delivery of plant-made biologics.
Collectively, the features and capabilities of ExpressTec enable cost-effective production that lowers economic barriers to routine use on a global scale.
Infectious enteric diseases are a global public health problem, particularly in developing countries. Infectious diarrhea alone affects nearly 2 billion people globally and kills half a million children every year. Funded in part by a grant from the Bill and Melinda Gates Foundation, Ventria Bioscience’s VEN BETA program is aimed at developing a new therapeutic targeting infectious enterotoxigenic E. coli, based on the oral delivery of recombinant breastmilk proteins produced using ExpressTec.
Inflammatory diseases of the gut, such as inflammatory bowel disease (IBD), Crohn’s disease, and ulcerative colitis, are difficult to treat and negatively affect the health and quality of life of millions of people around the world. Based on science showing that breastmilk proteins exert immunomodulatory activity in the gut, Ventria Bioscience is developing its therapeutic product VEN120 to address unmet needs in IBD.